Aug 2026· MD-Onco· Vol 6, pp. 66-89· 0 citations· 98 references
TL;DR
Currently, there are no universal adjuvant chemotherapy agents, so the latest advances in genomic and epigenomic research of meningiomas are being explored for potential targeted therapy.
Abstract
Meningiomas are the most common primary intracranial tumors in adults, accounting for over 35 % of all intracranial tumors. Moreover, meningiomas occurring in children account for only 0.64 % of all meningiomas, and among intracranial tumors in children, meningiomas account for 1.42–5.00 % of cases. Because the risk of developing meningioma increases significantly with age, the proportion of healthcare costs associated with meningiomas in developed countries will continue to increase as the demographics shift toward an aging population. Compared to malignant glial tumors, meningiomas have been relatively poorly studied in terms of etiologic risk factors. Meningiomas can also be part of hereditary diseases. These tumors are primarily benign and can be observed, but the preferred treatment method is complete tumor resection, which provides good results.
According to the World Health Organization, 5-year survival rate for grade I meningioma is over 80 %. Meningiomas with a heterogeneous morphological picture or located in difficult-to-reach anatomical locations represent a difficult task in terms of treatment and prediction of the outcome. Radiation therapy is often used for atypical, anaplastic, recurrent, and surgically inaccessible benign meningiomas. However, the method, regimen, dose, and timing of radiation therapy remain uncertain and are areas of active research, with clinical trials ongoing. Currently, there are no universal adjuvant chemotherapy agents, so the latest advances in genomic and epigenomic research of meningiomas are being explored for potential targeted therapy. Advances in genomics and molecular characterization of meningiomas have revealed potential for more detailed classification, description of disease progression, prognosis, and estimation of recurrence rates.
This review aims to analyze and summarize current data on meningiomas, their etiology, molecular characteristics, diagnostics, and treatment methods, and lists currently ongoing clinical trials.
Meningiomas are the most common primary intracranial neoplasms. Most meningiomas arise in intracranial or intraspinal locations. Meningiomas involving the orbits are much rarer. They can be further classified as primary, of orbital origin or secondary, arising intracranially and extending into the orbit. Diagnosing men...
Neeti Goyal, Arun Neog, Khaleel Machakuri et al.· Journal of Laboratory Physic...· 0 citations
Pediatric meningiomas are rare neoplasms that exhibit unique biological behavior, distinct from their adult counterparts in terms of histology, location, and molecular features. This chapter provides an in-depth review of the current understanding of pediatric meningiomas, integrating classical clinical, radiological,...
Javier Terrazo-Lluch, J. Murillo, Roberto García-Navarrete et al.· IntechOpen eBooks· 0 citations
ABSTRACT INTRODUCTION Meningioma is one of the most common central nervous system tumors; however, metastatic lesions are extremely rare. Particularly, hepatic metastasis from meningioma is uncommon, and its diagnosis and optimal management remain undefined. CASE PRESENTATION A 70-year-old man with a history of left pa...
Yuki Hirase, Haruhi Fukuhisa, Akihiko Sakamoto et al.· Surgery Case Reports· 0 citations
In this cohort, neither extent of resection nor adjuvant radiotherapy reached a statistically significant improvement in overall survival, whereas both were associated with delayed tumor recurrence.
Y. Miao, Hai-Bin Wan, Xin-Yan Zhao et al.· Frontiers in Surgery· 0 citations
Meningioma is the most common primary intracranial tumor in adults. Most meningiomas have an indolent growth pattern, but some can grow quickly. The World Health Organization (WHO) classification system is the gold standard for tumor grading and relies predominantly on histopathology and limited molecular alterations....
Leeor S. Yefet, Gelareh Zadeh, F. Nassiri· Neurotherapeutics· 2 citations